ESR2 and endometriosis: Conversely, evodiamine has the ability to impede the epigenetic alterations induced by EBV/LMP1 on the ERβ promoter, consequently suppressing the development of endometriosis initiated by EBV/LMP1 pretreatment (see Figure 8).